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The Fas/Fap-1/Cav-1 Complex Regulates IL-1RA Secretion in Mesenchymal Stem
Cells to Accelerate Wound Healing
Abstract
Mesenchymal stem cells (MSCs) are capable of secreting exosomes, extracellular vesicles, and cytokines
to regulate cell and tissue homeostasis. However, it is unknown whether MSCs use a specific exocytotic
fusion mechanism to secrete exosomes and cytokines. We show that Fas binds with Fas-associated
phosphatase–1 (Fap-1) and caveolin-1 (Cav-1) to activate a common soluble N-ethylmaleimide–sensitive
factor (NSF) attachment protein receptor (SNARE)–mediated membrane fusion mechanism to release
small extracellular vesicles (sEVs) in MSCs. Moreover, we reveal that MSCs produce and secrete
interleukin-1 receptor antagonist (IL-1RA) associated with sEVs to maintain rapid wound healing in the
gingiva via the Fas/Fap-1/Cav-1 cascade. Tumor necrosis factor–α (TNF-α) serves as an activator to upregulate Fas and Fap-1 expression via the nuclear factor κB pathway to promote IL-1RA release. This
study identifies a previously unknown Fas/Fap-1/Cav-1 axis that regulates SNARE-mediated sEV and
IL-1RA secretion in stem cells, which contributes to accelerated wound healing.
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Abstract
Author Manuscript

Mesenchymal stem cells (MSCs) are capable of secreting exosomes, extracellular vesicles, and
cytokines to regulate cell and tissue homeostasis. However, it is unknown whether MSCs use a
specific exocytotic fusion mechanism to secrete exosomes and cytokines. We show that Fas binds
with Fas-associated phosphatase–1 (Fap-1) and caveolin-1 (Cav-1) to activate a common soluble
N-ethylmaleimide–sensitive factor (NSF) attachment protein receptor (SNARE)–mediated
membrane fusion mechanism to release small extracellular vesicles (sEVs) in MSCs. Moreover,
we reveal that MSCs produce and secrete interleukin-1 receptor antagonist (IL-1RA) associated
with sEVs to maintain rapid wound healing in the gingiva via the Fas/Fap-1/Cav-1 cascade. Tumor
necrosis factor–! (TNF-!) serves as an activator to up-regulate Fas and Fap-1 expression via the
nuclear factor "B pathway to promote IL-1RA release. This study identifies a previously unknown
Fas/Fap-1/Cav-1 axis that regulates SNARE-mediated sEV and IL-1RA secretion in stem cells,
which contributes to accelerated wound healing.
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INTRODUCTION
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Mesenchymal stem cells (MSCs) are capable of self-renewal and differentiation into
mesenchymal and non-mesenchymal lineages (1, 2). MSCs have been used therapeutically
for tissue regeneration and auto-immune disease treatment (3–12). Recent emerging
evidence shows that multiple mechanisms contribute to MSC-based therapies in which
secretion of cytokines, growth factors, and small extracellular vesicles (sEVs) such as
exosomes may serve as paracrine or autocrine mediators to regulate immune responses and
tissue regeneration (13–15). MSCs have been identified to secrete at least three types of
exosomes (16); these exosomes represent an important mode of intercellular
communication. It is well known that a variety of cells, including neuroendocrine,
endocrine, exocrine, and immune cells, use different mechanisms to secrete EVs and that
soluble N-ethylmaleimide–sensitive factor (NSF) attachment protein receptor (SNARE)–
dependent exocytotic fusion plays a major role in the exocytosis of these EVs (17, 18).
Dysfunction of the secretion process may lead to various human diseases, such as
schizophrenia, Alzheimer’s disease, diabetes, and albinism (19–22). However, it is unknown
whether and, if so, how stem cells use an exocytotic fusion mechanism to secrete sEVs.

Author Manuscript

Mammalian adult cutaneous wound healing can be regulated by numerous secreted factors
including cytokines, growth factors, chemokines, and EVs (23, 24). MSC-derived exosomes
play an important role in cutaneous wound healing, by reducing heat stress–induced
apoptosis (25) and promoting collagen synthesis and angiogenesis (26). Compared to adult
cutaneous wounds, fetal wounds heal faster, are more akin to a scarless regeneration, and
display mild inflammation with fewer inflammatory cells and lower expression of
proinflammatory factors (27). Like fetal wounds, oral gingival/mucosal wounds heal faster
than cutaneous wounds and exhibit minimal scar formation (28), which may be due to
reduced inflammatory cell infiltration and proinflammatory factor production in the gingiva
(29–31). Thus, the secretion profile of MSCs may control accelerated wound healing in the
gingiva. Gingiva-derived MSCs (GMSCs) have a distinct neural crest origin and show
characteristics of self-renewal, multipotent differentiation, and immunomodulatory
capacities both in vitro and in vivo (32, 33). However, it is unknown whether GMSCs have a
unique secretory mechanism to regulate wound healing in the gingiva. Here, we show that
GMSCs use the Fas/Fas-associated phosphatase–1 (Fap-1)/caveolin-1 (Cav-1) complex to
activate SNARE-mediated membrane fusion to secrete higher amounts of interleukin-1
receptor antagonist (IL-1RA)–expressing sEVs to accelerate wound healing in the gingiva.

RESULTS
Author Manuscript

GMSCs produce and secrete higher amounts of IL-1RA–expressing sEVs than skin MSCs
To explore whether MSCs use a unique mechanism to secrete sEVs, we first isolated
exosome-like sEVs from the culture supernatant of several MSCs, including mouse and
human bone marrow MSCs (BMMSCs), GMSCs, and skin MSCs (SMSCs). We found that
both mouse and human GMSCs secreted higher amounts of sEV-associated proteins, and
SMSCs secreted lower amounts of sEV-associated proteins in the culture supernatant
compared to GMSCs (Fig. 1A and fig. S1A). We verified that these exosome-like sEVs
showed standard exosome microstructure and expressed exosome-associated proteins CD63,
Sci Transl Med. Author manuscript; available in PMC 2018 December 28.
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CD9, and CD81 (Fig. 1B and fig. S1B). Cytokine array analysis showed that GMSC-derived
sEVs contained higher amounts of IL-1RA, a natural inhibitor of the proinflammatory
cytokine IL-1# (34), compared to sEVs from SMSCs (fig. S1C). Because wound healing in
the gingiva is faster than that in the skin (28) and MSC-derived exosomes play an important
role in cutaneous wound healing (25), we hypothesized that secretion of higher amounts of
sEVs and IL-1RA by GMSCs may contribute to a quick wound healing process in the
gingiva. To further confirm that sEVs contain IL-1RA, a differential centrifugation
approach, followed by sucrose cushion to isolate sEVs at a higher purity grade (35, 36), was
used to isolate different sizes of EVs in the culture supernatant of GMSCs and SMSCs (Fig.
1C). We showed that cell lysate, cell debris and large EVs, and sEVs from GMSCs and
SMSCs expressed IL-1RA; however, IL-1RA was not expressed in mixed EVs (Fig. 1D and
fig. S1D), suggesting that IL-1RA might be released via sEVs. To rule out potential
contributions from nonvesicular particles, we loaded the crude EV fraction from differential
centrifugation on a sucrose gradient (36). We found that IL-1RA mainly appeared in 3 light
fractions out of the 10 high-speed ultra-centrifugation fractions and matched the expression
with CD63, CD9, and CD81 (fig. S1E), which was consistent with a previous report that
MSC-derived sEVs usually float in gradients with 1.10 to 1.18 g/ml (37). To demonstrate
that the sEV-associated secretion is the major pathway of IL-1RA secretion, we collected the
supernatant from each step of differential centrifugation as described (fig. S1F). After the
initial steps of centrifugation, we found that the supernatants collected from SN I, SN II, and
SN III sections contained similar amounts of IL-1RA. However, the amount of IL-1RA
reduced from 134.07 pg/ml in SN III to 12.22 pg/ml in SN IV after ultracentrifugation (fig.
S1G). We next showed that the isolated sEVs expressed equal amounts of IL-1RA compared
with the concentrated supernatant collected before ultracentrifugation (SN III), but the
concentrated proteins from the ultracentrifuged supernatant (SN IV) showed a markedly
decreased amount of IL-1RA (fig. S1H). We further performed immunogold electron
microscopy to show that IL-1RA was detected on the surface of purified exosome-like EVs
(fig. S1I). These results support our conclusion that IL-1RA is secreted by sEVs.
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To further confirm the presence of IL-1RA–positive sEVs, we transfected GMSCs with
IL-1RA–enhanced green fluorescent protein (EGFP) plasmids and then used superresolution stimulated emission depletion (STED) microscopy to show colocalization of
IL-1RA with CD63 and CD81 (Fig. 1E). To verify EV–IL-1RA exocytosis, GMSCs were
cotransfected with plasmids expressing IL-1RA–EGFP fusion protein and CD63-mCherry
fluorescent protein, and colocalization was observed by total internal reflection fluorescence
(TIRF) microscopy (Fig. 1F). The sequential fluorescent images displayed fusion of
individual IL-1RA–EGFP/CD63-mCherry double-positive exosome-like EVs with the
plasma membrane (Fig. 1F). Moreover, we found that IL-1RA–EGFP/CD63-mCherry
double-positive exosome-like EVs fused with the plasma membrane in living GMSCs
(movie S1).
Next, we showed that GMSCs secreted a higher amount of IL-1RA in the culture
supernatant compared to SMSCs, as assessed by enzyme-linked immunosorbent assay
(ELISA) (Fig. 1G). Western blotting showed that both human and mouse GMSCs expressed
elevated IL-1RA relative to SMSCs (Fig. 1H and fig. S1J). IL-1RA was coexpressed with
MSC markers CD105, CD44, and CD90 in GMSCs and SMSCs (Fig. 1I and fig. S1K).
Sci Transl Med. Author manuscript; available in PMC 2018 December 28.
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There are four isotypes of IL-1RA: One isoform is secreted (sIL-1RA), whereas the three
others lack a consensus leader peptide and remain intracellular (icIL-1RA1, icIL-1RA2, and
icIL-1RA3) (34). GMSCs express a similar amount of sIL-1RA mRNA, but a significantly
higher amount of icIL-1RA mRNA compared to SMSCs (Fig. 1, J and K), suggesting that
altered expression of IL-1RA is mainly caused by icIL-1RA. Because icIL-1RA does not
have a signaling peptide that marks it for transport outside of the cells, it is possible that
icIL-1RA is instead packaged into sEVs and transported to the extracellular
microenvironment.
Fas controls IL-1RA–sEV release in MSCs

Author Manuscript
Author Manuscript

Our previous study showed that Fas controls monocyte chemoattractant protein–1 (MCP-1)
secretion to regulate MSC-based immune therapies (4). We therefore hypothesized that Fas
may control IL-1RA–sEV release to modulate wound healing. We showed that GMSCs
expressed elevated Fas in the cytoplasm compared to SMSCs (Fig. 2A). GMSCs and SMSCs
from Fas-deficient MRL/lpr mice showed reduced capacity to secrete sEV protein to the
culture supernatant (Fig. 2B and fig. S2A). EVs from MRL/lpr GMSCs and SMSCs
expressed reduced CD63, CD9, CD81, and IL-1RA compared to wild-type (WT) control
GMSCs (Fig. 2C and fig. S2B). We further confirmed that GMSCs from MRL/lpr mice
showed reduced IL-1RA secretion into the culture supernatant, along with elevated
cytoplasmic accumulation of IL-1RA when compared to WT control GMSCs (Fig. 2, D and
E). In addition, immunostaining showed IL-1RA colocalized with Fas where it accumulated
in Fas-deficient MRL/lpr GMSCs (Fig. 2F). Overexpression of Fas in MRL/lpr GMSCs
rescued IL-1RA secretion into the culture supernatant and reduced the cytoplasmic
expression of IL-1RA (Fig. 2, G and H). When Fas expression was knocked down in
GMSCs by small interfering RNA (siRNA), IL-1RA secretion into the culture supernatant
was reduced; however, cytoplasmic IL-1RA was increased (Fig. 2, I and J), which was also
observed in MRL/lpr GMSCs. These data suggest that Fas may control IL-1RA–sEV release
in GMSCs.
Fas bound with Fap-1 and Cav-1 controls IL-1RA–sEV release

Author Manuscript

Fap-1 is a protein tyrosine phosphatase capable of binding to the cytosolic domain of Fas
(38), and Cav-1 can also bind to Fas to regulate apoptosis (39). However, it is unknown
whether Fap-1 and Cav-1 are involved in Fas-controlled sEV/cytokine release. SNARE
family proteins mediate the exocytosis of cellular transport vesicles with the cell membrane;
some of the key molecules in this family are synaptosome-associated protein of 25 kDa
(SNAP25) and vesicle-associated membrane protein (VAMP) (18). We speculated that Fas
might control IL-1RA–sEV release through interaction with Fap-1, Cav-1, and SNARE
proteins. We saw that Fas coimmunoprecipitated with Fap-1, Cav-1, SNAP25, and VAMP5;
this coimmunoprecipitation (co-IP) was absent in Fas-deficient MRL/lpr GMSCs (Fig. 3A
and fig. S3A). Immunostaining confirmed that Fas colocalized with Fap-1, Cav-1, SNAP25,
and VAMP5, and that Fap-1 colocalized with Cav-1 in WT GMSCs (Fig. 3B and fig. S3B).
To assess the functional role of Fap-1/Cav-1 in IL-1RA–sEV release, we examined Fap-1
and Cav-1 knockout GMSCs and SMSCs. Fap-1 and Cav-1 knockout GMSCs and SMSCs
showed reduced sEV secretion into the culture supernatant (Fig. 3C and fig. S3C). sEVs
from Fap-1 and Cav-1 knockout GMSCs and SMSCs expressed reduced CD63, CD9, CD81,
Sci Transl Med. Author manuscript; available in PMC 2018 December 28.
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and IL-1RA compared to control GMSCs and SMSCs, respectively (Fig. 3D and fig. S3D).
To further dissect the functional role of Fas/Fap-1/Cav-1, we showed that there was no
difference in the expression of Fap-1 and Cav-1 in Fas-deficient MRL/lpr GMSCs (Fig. 3E),
but there was reduced secretion of exosome-associated proteins and IL-1RA into the culture
supernatant and there were elevated amounts of IL-1RA in the cytoplasm (Fig. 2, B to E).
Knockout of Fap-1 or Cav-1 in GMSCs reduced IL-1RA secretion into the culture
supernatant and increased cytoplasmic IL-1RA, but failed to affect the expression of Fas/
Cav-1 or Fas/Fap-1 (Fig. 3, E and F). Knockdown of Fas, Fap-1, or Cav-1 by siRNAs in
GMSCs failed to affect the expression of the other two members, but decreased IL-1RA
secretion into the culture supernatant with increased cytoplasmic accumulation of IL-1RA
(fig. S3, E and F), which is the same as that observed in MRL/lpr, Fap-1, and Cav-1
knockout GMSCs. These data suggest that Fas/Fap-1/Cav-1 control IL-1RA release. In
addition, knockdown of Fas, Fap-1, or Cav-1 failed to affect the expression of SNAP25 and
VAMP5 (fig. S3E). To test whether SNAP25 and VAMP5 are also involved in Fas/Fap-1/
Cav-1–controlled IL-1RA release, we showed that knockdown of SNAP25 or VAMP5 by
siRNA failed to affect the expression of Fas, Fap-1, and Cav-1 (fig. S3E), but reduced
IL-1RA secretion into the culture supernatant along with increased cytoplasmic
accumulation of IL-1RA (fig. S3, E and F). These data suggest that Fas/Fap-1/Cav-1
machinery may control IL-1RA release via SNAP25/VAMP5.
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We next determined how Fas binds to the downstream complex SNAP25/VAMP5 and how
Fas/Fap-1/Cav-1 bind together to control exosome/IL-1RA release. We performed IP using
Fas-deficient MRL/lpr, Fap-1 knockout, and Cav-1 knockout GMSCs to show that knocking
out Fap-1 failed to reduce the co-IP of Fas with Cav-1, SNAP25, and VAMP5, whereas
knockout of Cav-1 failed to affect the co-IP of Fas with Fap-1 but resulted in the reduction
of Fas co-IP with SNAP25 and VAMP5 (Fig. 3G and fig. S3G). These data suggest that the
binding of Fas with SNAP25/VAMP5 is mediated by Cav-1. To test how Fap-1 binds with
the other proteins, we showed that Fas-deficient MRL/lpr GMSCs failed to affect the co-IP
of Fap-1 with Cav-1, SNAP25, and VAMP5, whereas knocking out Cav-1 expression failed
to affect the co-IP of Fap-1 with Fas, but resulted in the reduction of Fap-1 co-IP with
SNAP25 and VAMP5 (Fig. 3H and fig. S3H). We next used immunocytofluorescence
staining to confirm that Fap-1 was colocalized with SNAP25 and VAMP5 (fig. S3I). These
data suggest that the binding of Fap-1 with SNAP25/VAMP5 is also mediated by Cav-1.
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To examine how Cav-1 binds with the other proteins, we showed that MRL/lpr or Fap-1
knockout GMSCs failed to affect the co-IP of Cav-1 with Fap-1 or Fas and also failed to
affect the co-IP of Cav-1 with SNAP25 and VAMP5 (Fig. 3I and fig. S3J).
Immunocytofluorescence staining further confirmed that Cav-1 was colocalized with
SNAP25 and VAMP5 (fig. S3K). Together, these data suggest that Fas/Fap-1/Cav-1 bind
together, but these events occur independently of one another; that the binding between
Cav-1 and SNAP25/VAMP5 is independent of Cav-1 binding with Fas/Fap-1; and that the
binding of Fas/Fap-1 with SNAP25/VAMP5 is mediated by Cav-1. Fas-deficient MRL/lpr
and Fap-1 knockout GMSCs had marked clustering of Cav-1 expression in the cytoplasm,
but Cav-1 knockout failed to affect the colocalization or the distribution of Fas and Fap-1
(Fig. 3J). These data imply that Fas/Fap-1 may bind to Cav-1 and control its trans-location,
thereby controlling SNAP25/VAMP5-related IL-1RA–sEV secretion (fig. S3L).
Sci Transl Med. Author manuscript; available in PMC 2018 December 28.
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Tumor necrosis factor–! activated IL-1RA–sEV release via up-regulation of Fas/Fap-1
expression in MSCs
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Because tumor necrosis factor–! (TNF-!) can increase the production of MSC-secreted
growth factors (40), we used TNF-! and interferon-$ (IFN-$) to treat GMSCs and found
that only TNF-! significantly enhanced the secretion of IL-1RA in the culture supernatant in
a dose-dependent manner (P < 0.01) (Fig. 4A). Moreover, we found that TNF-!–treated
GMSCs and SMSCs showed increased capacity to secrete sEV-associated protein to the
culture supernatant (Fig. 4B and fig. S4A). sEV-associated protein from TNF-!–treated
GMSCs and SMSCs expressed elevated amounts of CD63, CD9, CD81, and IL-1RA
compared to control GMSCs (Fig. 4C and fig. S4B). To determine whether TNF-! affects
Fas/Fap-1–controlled sEV/IL-1RA release, we showed that TNF-! treatment up-regulated
the expression of Fas, Fap-1, and IL-1RA, but not Cav-1 in control and MRL/lpr GMSCs
(Fig. 4D). TNF-! treatment–induced secretion of IL-1RA and sEV-associated protein was
significantly reduced in MRL/lpr GMSCs when compared to control GMSCs (P < 0.001)
(Fig. 4E and fig. S4C). These data suggest that TNF-! may serve as an activator to enhance
IL-1RA–EV release through up-regulation of Fas and Fap-1. To confirm that TNF-!
regulates Fas, we used siRNA to knock down Fas expression in GMSCs and showed that
TNF-! treatment resulted in reduced secretion of IL-1RA into the culture supernatant with
elevated intracellular IL-1RA compared to control GMSCs (fig. S4, D and E). Fap-1 and
Cav-1 knockout GMSCs showed that TNF-! treatment resulted in elevated intracellular Fas
and IL-1RA in Fap-1 knockout GMSCs and elevated intracellular Fas, Fap-1, and IL-1RA in
Cav-1 knockout GMSCs (Fig. 4, F and G). TNF-! treatment–induced secretion of IL-1RA
and exosome protein in the culture supernatant was significantly reduced in Fap-1 and Cav-1
knockout GMSCs when compared to control GMSCs (P < 0.001) (Fig. 4H and fig. S4F). Fas
and Cav-1 translocated to the cell membrane region at 0.5 to 1 hour after TNF-! treatment
(Fig. 4I). Fap-1 was also distributed near the membrane region along with Cav-1 at 0.5 to 1
hour after TNF-! treatment (fig. S4G). Western blotting showed that TNF-! treatment
increased the expression of Fas and Cav-1 in the cell membrane as well as Fas and Fap-1 in
the cytoplasm in GMSCs, but decreased the expression of Cav-1 in the cytoplasm (Fig. 4J).
These data indicate that TNF-! treatment induces the membrane translocation of Fas and
Cav-1 to control Fas/Fap-1/Cav-1–mediated IL-1RA release. Because TNF-! is able to
activate the nuclear factor "B (NF-"B) pathway (41) and NF-"B is capable of regulating the
transcription of Fas and Fap-1 (42), we further showed that treatment with an NF-"B
inhibitor, pyrrolidinedithiocarbamate (PDTC), was able to block TNF-!–induced IL-1RA
release in GMSCs (fig. S4H).
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We next determined whether TNF-! could activate IL-1RA–EV release. When GMSCs
were transfected with plasmids expressing IL-1RA–EGFP and the vesicular organelles were
stained with LysoTracker TIRF microscopy showed that IL-1RA–EGFP overlapped with
LysoTracker-positive EVs (fig. S4I). After 0.5 hours of TNF-! treatment, IL-1RA–EGFP
exosome-like EVs fused with the plasma membrane in living GMSCs (movie S2).
Sequential fluorescent images displayed fusion of individual IL-1RA–EGFP–positive
exosome-like EVs to the plasma membrane in response to TNF-! treatment (fig. S4I). To
confirm TNF-!–activated IL-1RA–positive exosome-like EV release, GMSCs were
cotransfected with plasmids expressing IL-1RA–EGFP fusion protein and CD63-mCherry
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fluorescent protein (Fig. 4K). After 0.5 hours of TNF-! treatment, colocalization of
IL-1RA–EGFP and CD63-mCherry exosome-like EVs was observed by TIRF microscopy
(Fig. 4K). Moreover, we found intensive IL-1RA–EGFP/CD63-mCherry double-positive
exosome-like EVs fused with the plasma membrane in living GMSCs (movie S3), and
sequential fluorescent images displayed fusion of individual IL-1RA–EGFP/CD63-mCherry
double-positive exosome-like EVs to the plasma membrane after TNF-! treatment (Fig.
4K). These data indicate that TNF-! up-regulates Fas/Fap-1 expression via the NF-"B
pathway to induce the membrane translocation of Cav-1, thereby enhancing IL-1RA release
in GMSCs (fig. S4J).
GMSCs produce high amounts of IL-1RA to facilitate wound healing in the gingiva
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Wound healing in the gingiva is faster than that in the skin (28), and we showed that GMSCs
and gingival wound tissue have higher expression of IL-1RA than SMSCs and skin wound
tissue, respectively (Fig. 1, G and H, and fig. S5A). We examined whether the IL-1RA
produced by GMSCs contributed to accelerated wound healing in the gingiva using
immunohistofluorescence staining and found that GMSCs expressed IL-1RA at the margins
of wound areas (fig. S5B). Staining showed that IL-1RA was coexpressed with neural crest–
derived MSCs in gingival wound tissue in Wnt1-Cre-tdTomato mice, further confirming that
GMSCs produce IL-1RA (fig. S5C). A previous study reported that IL-1RA knockout mice
showed impaired cutaneous wound healing (43). We found that gingival healing was
significantly delayed in IL-1RA knockout mice at 3, 5, and 7 days post-wounding compared
to WT control mice (3 days, P < 0.01; 5 days, P < 0.001; 7 days, P < 0.001) (Fig. 5, A and B,
and fig. S5D). Moreover, injection of IL-1RA neutralizing antibody significantly inhibited
gingival wound healing at 3, 5, and 7 days after wound creation compared to the control
mice (3 days, P < 0.05; 5 days, P < 0.001; 7 days, P < 0.001) (Fig. 5C and fig. S5E).
Because IL-1RA was also detected in SMSCs near the margin of cutaneous wound areas
(fig. S5F), we showed that IL-1RA knockout mice have delayed wound healing in a fullthickness square cutaneous wound model at 5, 7, 10, and 14 days after wound creation when
compared to WT control mice (fig. S5, G to I). This effect was confirmed in a circular
cutaneous wound model (fig. S5J). These data suggest that MSC-secreted IL-1RA plays a
crucial role in gingival and cutaneous wound healing.
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To further examine the role of IL-1RA in wound healing, anakinra, a Food and Drug
Administration (FDA)–approved form of recombinant IL-1RA, was locally injected into
wounds. We found that gingival wound healing was significantly accelerated by
administration of anakinra at 3, 5, and 7 days after wound creation compared to the control
group (3 days, P < 0.001; 5 days, P < 0.001; 7 days, P < 0.01) (Fig. 5D and fig. S5, K and
L). Moreover, administration of anakinra significantly promoted cutaneous wound healing at
5, 7, 10, and 14 days after wound creation compared to the control group (P < 0.001) (Fig. 5,
E and F, and fig. S5M). This effect was also confirmed in a circular cutaneous wound model
(fig. S5N).
To confirm the effect of GMSC-secreted IL-1RA–sEV on wound healing, we isolated sEVs
from WT and IL-1RA knockout GMSCs and locally injected them into the gingival wounds
in IL-1RA knockout mice. We found that administration of WT control GMSC-derived
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sEVs significantly promoted gingival wound healing (P < 0.001), whereas injection of
IL-1RA knockout GMSC–derived sEVs failed to accelerate the wound healing (Fig. 5, G
and H, and fig. S5O). To confirm the effect of TNF-! on GMSC sEV secretion, we isolated
sEVs from TNF-!–treated GMSCs and used these sEVs to treat gingival wounds. We found
that local injection of TNF-!–treated GMSC-derived sEVs promoted the closure of wound
healing at 7 days after wound creation in IL-1RA knockout mice as compared to injection of
WT control sEVs (Fig. 5, G and H). Similar to gingival wound healing, we isolated sEVs
from WT and IL-1RA knockout SMSCs and locally injected these sEVs into the cutaneous
wounds in IL-1RA knockout mice. We found that administration of WT SMSC–derived
sEVs significantly promoted cutaneous wound healing at 3, 5, 7, 10, and 14 days after
wounding in IL-1RA knockout mice (P < 0.05), whereas injection of IL-1RA knockout
SMSC-derived sEVs failed to accelerate the wound healing (fig. S5, P to R). To confirm the
effect of TNF-! on SMSC sEVs, we isolated sEVs from TNF-!–treated SMSCs and locally
injected these sEVs into cutaneous wounds. We found that administration of TNF-!–treated
SMSC-derived sEVs further potentiated wound healing at 7, 10, and 14 days after wound
creation in IL-1RA knockout mice as compared to injection of sEVs from WT SMSCs (fig.
S5, P to R). These results suggest that MSC-derived IL-1RA–EVs can serve as a therapeutic
agent for wound healing.
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Previous studies reported that diabetic mice showed a delayed wound healing process (44,
45). It would therefore be interesting to know whether diabetic GMSCs have similar
characteristics to normal GMSCs. We showed that GMSCs from diabetic mice had reduced
capacity to secrete sEV proteins to the culture supernatant (fig. S6A). Moreover, GMSCs
from diabetic mice showed reduced IL-1RA secretion into the culture supernatant, along
with elevated cytoplasmic accumulation of IL-1RA and decreased Fas expression when
compared to WT GMSCs (fig. S6, B and C). Streptozotocin-induced type 1 diabetic mice
exhibited significantly delayed gingival and skin wound healing compared to WT mice
(gingival, P < 0.001; skin, P < 0.05) (fig. S6, D to I). Injection of WT GMSC–derived sEVs
partially rescued the delayed wound healing; however, injection of IL-1RA knockout
GMSC–derived sEVs failed to rescue the delayed wound healing in diabetic mice (fig. S6, D
to I). These results suggest that sEVs containing IL-1RA can partially ameliorate the
delayed wound healing process in diabetic mice.
Fas-controlled IL-1RA secretion regulates wound healing in the gingiva and skin
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Next, we examined whether Fas-controlled IL-1RA release governs the wound healing
process. Immunohistofluorescence staining showed that Fas was coexpressed with IL-1RA
in both gingival and cutaneous wound sites in WT mice (fig. S7, A and B). Fas-deficient
MRL/lpr mice exhibited significantly delayed gingival wound healing at 5 and 7 days after
wounding compared to WT control mice (P < 0.001), and injection of anakinra partially
rescued the delayed wound healing (Fig. 6, A and B, and fig. S7C). In addition, MRL/lpr
mice exhibited significantly delayed cutaneous wound healing at 5, 7, 10, and 14 days after
wounding compared to the WT control mice (5 days, P < 0.01; 7 days, P < 0.01; 14 days, P
< 0.001), and injection of anakinra partially rescued the delayed wound healing in MRL/lpr
mice (Fig. 6, C and D, and fig. S7D). These results suggest that Fas may control the IL-1RA
release in MSCs and, thus, govern the wound healing process. In summary, these results
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suggest that MSCs use the Fas/Fap-1/Cav-1 axis to regulate SNARE-mediated IL-1RA–sEV
release to regulate wound healing in the gingiva. TNF-! serves as an activator to up-regulate
Fas and Fap-1 to enhance IL-1RA–sEV release (fig. S8).

DISCUSSION

Author Manuscript

The trafficking of secretory vesicles to the plasma membrane of eukaryotic cells is essential
for intercellular communication through the release of a variety of extracellularly acting
molecules. Secretory vesicles and some extracellular molecules (plasma proteins, antibodies,
and extracellular matrix components) are also secreted by a constitutive exocytotic pathway
(17, 46). Regulation of exocytosis has been studied in a wide range of cell types specialized
to secrete large amounts of secretory products, including neuroendocrine, endocrine, and
exocrine cells. Most exocytotic secretory processes are mediated through mechanisms with
SNARE protein–dependent exocytotic fusion (17, 18). Cells that use this mechanism include
astrocytes, which are cells of the central nervous system that secrete chemical mediators
(47), and # cells, which are cells of the endocrine system that secrete insulin (48). However,
it is unknown whether and how stem cells use exocytotic fusion mechanisms to secrete EVs.
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The secretion of cytokines by immune cells in response to inflammatory or infectious
stimuli plays an important role in the regulation of immune response. The trafficking
machinery and secretory (exocytotic) pathways are complex and highly regulated in immune
cells. The majority of secretory cytokines contain N-terminal or internal signal peptides that
direct their sorting into the endoplasmic reticulum (ER) for synthesis as either soluble or
transmembrane precursors and are then transported to the extracellular space or the plasma
membrane through the ER-Golgi secretory pathway, which is called the conventional
secretory pathway (49). Secretion of TNF by macrophages is an example of the conventional
secretory pathway that proceeds via granule-mediated and constitutive routes. MSCs secrete
a variety of growth factors, immunomodulatory cytokines, and exosomes (13–15, 24),
serving as paracrine regulators. However, whether MSCs serve as secretory cells, using a
unique mechanism to release cytokines and EVs, is largely unknown.

Author Manuscript

Here, we used MSCs as a model to dissect a distinctive cytokine secretion mechanism in
stem cells in which Fas/Fap1/Cav1 machinery controls SNAP25/VAMP5–associated
IL-1RA–sEV exocytosis. Cav-1 is the main component of lipid rafts that dynamically
participate in a number of cellular processes, including signal transduction, lipid regulation,
and membrane trafficking (50). Cav-1 is known to bind to Fas and is perhaps involved in the
apoptotic process (39). As expected, Cav-1 knockout mice showed impaired cutaneous
wound healing (51). Cav-1 also binds with SNAP25 and is associated with neurosecretion
(52). It is known that Fap-1, a protein tyrosine phosphatase, binds with Fas (38). We found
that Fap-1 also binds with Cav-1. Recent studies reveal that interactions between
synaptotagmin-1 and the SNARE complex can promote neuronal exocytotic fusion (53).
Rab27a and Rab27b control multivesicular endosomes docking at the plasma membrane to
regulate exosome secretion in HeLa cells (54). Our findings identify a role for the Fas/Fap-1/
Cav-1 complex in MSC-mediated IL-1RA–sEV secretion.
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The surrounding microenvironment may stimulate paracrine factor production to promote
MSC-mediated tissue homeostasis. Once MSCs have encountered the microenvironment of
injured tissues, many factors, including inflammatory cytokines (such as TNF-!, IFN-$, and
IL-1), toxins of infectious agents, and hypoxia, can stimulate the release of various
regulatory molecules (14). Elevation of internal Ca2+ concentrations can activate astrocytes
to initiate inter-cellular communication by SNARE-dependent glutamate vesicle release
(55), and glucose stimulates SNARE-dependent insulin vesicle exocytosis in # cells (48).
Components of the microenvironment, including the wound milieu, may stimulate paracrine
factor production to promote MSC-mediated tissue repair and immune regulation. We found
that TNF-! is able to activate sEV/IL-1RA release via up-regulating Fas/Fap-1 expression. It
is known that the interaction of TNF-! with TNF-!R may activate the NF-"B pathway and
induce the expression of prosurvival genes including B cell lymphoma 2 (Bcl-2), X-linked
inhibitor of apoptosis protein (XIAP), and the FLICE-inhibitory protein (FLIP);
furthermore, FLIP can directly inhibit caspase-mediated cell apoptosis (41, 56). Here, we
found that TNF-! activates IL-1RA release in MSCs via the NF-"B pathway to promote
wound healing. Supporting evidence for this conclusion came from a previous study that
also showed that TNF-! could promote human MSCs to secrete growth factors such as
vascular endothelial growth factor (40).

Author Manuscript

Oral gingival/mucosal wounds heal faster than cutaneous ones, with minimal scar formation
(28) and reduced inflammatory cell infiltration (29–31). A previous study reported the
beneficial effects of MSCs on wound healing, by promoting M2 macrophage polarization
(57). Recent studies showed that MSC-derived exosomes are capable of transporting active
proteins and microRNAs to communicate with the extracellular environment (13, 16, 58,
59). We also showed that sEVs from GMSCs and SMSCs contain many cytokines, among
which GMSC-derived sEVs contain a significantly higher amount of IL-1RA. Given that
IL-1RA is a natural inhibitor of the proinflammatory cytokine IL-1#, it modulates a variety
of IL-1–related immune and inflammatory responses (60–62), thus contributing to the rapid
wound healing of the gingiva. MSC-produced IL-1RA mediates the anti-inflammatory and
antifibrotic effect during lung injury in mice (63). Also, MSC-derived IL-1RA promotes
macrophage polarization and inhibits B cell differentiation (64). IL-1RA–deficient mice
show delayed cutaneous wound healing, spontaneous and lethal arteritis, and destructive
arthritis (43, 65, 66). Delivery of anakinra, a commercially available form of IL-1RA
approved by the FDA for treating rheumatoid arthritis and neonatal-onset multisystem
inflammatory disease (67, 68), into the wound area can reduce fibrotic invasion (69).
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It is well known that, unlike human skin wounds, mouse cutaneous wounds heal largely via
contraction, due to the nature of their loose skin with dense hair follicles. This might explain
why we only observed significant differences of wound closure at the later stages (5 days
after surgery). We found that IL-1RA knockout mice exhibited delayed wound healing in
both the gingiva and skin. Blockage of IL-1RA by submucosal injection of IL-1RA
neutralizing antibody at wound sites resulted in impaired gingival wound healing.
Conversely, injection of anakinra accelerated gingival and cutaneous wound healing, thus
highlighting the role of IL-1RA in promoting wound healing. MSC-derived exosomes may
also affect the wound healing process by other mechanisms, such as by delivery of Wnt4 to
promote proliferation of skin cells and by promoting collagen synthesis and angiogenesis in
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the wounded area (25, 26). We found that WT MSC–derived, but not IL-1RA knockout
MSC–derived, EVs promoted delayed wound healing in IL-1RA knockout or diabetic mice.
These results suggest that MSC-derived IL-1RA–sEV plays an important role in gingiva and
cutaneous wound healing. Exosome membrane proteins can interact with receptors in a
target cell or can be cleaved by proteases in the extracellular space to act as soluble ligands
that bind to the target cell surface (70). A previous study showed that exosomes carry active
Wnt proteins on their surface to induce Wnt signaling (71). Here, we found that IL-1RA was
detected on exosome-like EV membranes. This might explain why IL-1RA–sEV effectively
communicated with the extracellular environment in wound areas. In addition, sEVs may
contain the consensus leader peptide-containing isoform of IL-1RA, which may bind to a
receptor on sEV surface after targeting the luminal side of ER-Golgi secretory vesicles.
Further research is required to dissect the detailed mechanism(s) by which intracellular
isoforms of IL-1RA are shuttled to the membrane of exosome-like EVs. Other oral cavity
factors such as saliva and the microbiome may also affect gingival wound healing, and the
effect of epidermal stem cells is particularly important in the process of epithelialization
during cutaneous wound healing. Nevertheless, these studies support the notion that
IL-1RA–sEV plays a crucial role in regulating wound healing in both the gingiva and the
skin and suggest that anakinra and IL-1RA–positive sEVs can be used to improve cutaneous
wound healing.
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Here, we found that MSCs release IL-1RA using a mechanism by which Fas/Fap-1/Cav-1
regulate dynamic exocytosis of IL-1RA–EV. TNF-! serves as an activator to promote
IL-1RA–sEV exocytosis from MSCs. Our previous study showed that MSC-derived sEVs
are able to rescue Fas-deficient MSCs through a Fas reuse mechanism to improve miR-29b
release in recipient MSCs (58). These pieces of evidence suggest that sEVs play a crucial
role in biological cross-talk between MSCs and surrounding cells or recipient cells. This
study identifies an sEV/cytokine secretion mechanism used by MSCs that may play a crucial
role in MSC-based wound healing therapies.

MATERIALS AND METHODS
Study design
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Here, we used MSCs as a model to examine whether stem cells have a unique exocytic
fusion mechanism to release EVs and whether gingival MSCs secrete a high amount of EVs
with IL-1RA to contribute to accelerated wound healing. Three experimental studies were
designed: (i) We identified GMSC production and secretion of IL-1RA–expressing sEVs
using ultracentrifugation and sucrose gradient, immunoelectron microscopy, colocalization
of IL-1RA with EV markers observed by STED microscopy, living cell exocytosis of
IL-1RA–EGFP/CD63-mCherry double-positive exosome-like EVs observed by TIRF
microscopy, ELISA, and Western blotting; (ii) we used Western blotting, ELISA,
immunocytofluorescence staining, and co-IP in WT, gene knockout, and siRNA-treated
MSCs to reveal that MSCs use the Fas/Fap-1/Cav-1 axis to regulate SNARE-mediated EVs
and IL-1RA secretion; and (iii) we determined the therapeutic effect of recombinant IL-1RA
or IL-1RA/sEVs in accelerating gingival and cutaneous wound healing in WT, IL-1RA
knockout, MRL/lpr, and diabetic mouse models. The sample sizes for the in vivo studies
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were based on the resource equation because the effect size was unknown. Exact numbers
for each experiment are included in the figure legends. The investigators were not blinded
when conducting or evaluating the experiments. Mice were randomly assigned to the
treatment and control groups. Individual subject-level data for experiments where n < 20 are
included in table S1.
Animals
Female C57BL/6J, C3H/HeJ, B6.129S-Il1rntm1Dih/J (IL-1RA knockout), C3MRL-Faslpr/J
(MRL/lpr), and Cav1tm1Mls/J (Cav-1 knockout) mice were purchased from the Jackson
Laboratory. Age-matched 8- to 10-week female mice from the same background were used
in all experiments. All animal experiments were performed under institutionally approved
protocols for the use of animal research (University of Pennsylvania Institutional Animal
Care and Use Committee, #805478).
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Antibodies and reagents
Anti–IL-1RA and VAMP5 antibodies were purchased from Abcam. Anti-Fas antibody was
purchased from Millipore. Anti–Fap-1, Cav-1, SNAP25, CD105, CD90, CD44, CD63, CD9,
and CD81 antibodies were purchased from Santa Cruz Biotechnology. Anti–p-NF-"B p65
and NF-"B p65 antibodies were purchased from Cell Signaling. Anti–#-actin antibody was
purchased from Sigma-Aldrich. Alexa Fluor 488 and Alexa Fluor 568 secondary antibodies
were purchased from Invitrogen. Protein A/G PLUS-Agarose was purchased from Santa
Cruz Biotechnology. NF-"B inhibitor ammonium PDTC was purchased from SigmaAldrich.
Isolation of mouse and human bone marrow, gingival, and skin MSCs
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Stem cells from mouse and human tissue were isolated and cultured as reported by other
groups (72, 73) and our previous studies (4, 9, 32, 33, 74–80). Briefly, gingival and skin
tissues from mice were gently separated, minced, and digested with solution containing
collagenase type I (2 mg/ml) (Worthington Biochemical) and dispase II (4 mg/ml) (Roche
Diagnostics) in phosphate-buffered saline (PBS) for 1 hour at 37°C. Bone marrow cells were
flushed out from the bone cavities of femurs and tibias with 2% heat-inactivated fetal bovine
serum (FBS; Equitech-Bio) in PBS. Single-cell suspensions from the gingiva, skin, or bone
marrow were obtained by passing the cells through a 70-µm strainer (BD Biosciences). All
nucleated cells were seeded on 100-mm culture dishes (Corning) in complete media
containing !-minimum essential medium (!-MEM) (Invitrogen) supplemented with 20%
FBS, 2 mM l-glutamine (Invitrogen), 55 µM 2-mercaptoethanol (Invitrogen), penicillin (100
U ml−1), and streptomycin (100 µg ml−1) (Invitrogen), followed by an initial incubation for
48 hours at 37°C and 5% CO2. The cultures were washed with PBS twice to eliminate the
nonadherent cells. Attached cells were cultured for another 12 days under the same
conditions in the complete medium mentioned above. Skin MSCs were isolated and cultured
using the same procedure described for gingival MSCs. These single colonies were passaged
with frequent medium changes to eliminate potential hematopoietic cell contamination (72,
73). We further identified these MSCs and demonstrated that BMMSCs, GMSCs, and
SMSCs showed the capacity of self-renewal, assessed by fibroblast colony-forming units
and high rate of proliferation (fig. S9). Flow cytometric analysis confirmed that these MSCs
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were positive for the MSC surface markers CD44, CD90, CD105, and Sca-1, but were
negative for the hematological markers CD34 and CD45 (fig. S9). These MSCs also showed
the capacity for multipotent differentiation, including osteogenic, adipogenic, chondrogenic,
and neurogenic differentiation (fig. S9).
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Human bone marrow aspirates from healthy human adult volunteers (20 to 35 years of age)
were purchased from AllCells LLC. Human GMSCs and SMSCs were isolated from the
gingival and skin tissues obtained as remnants of discarded human tissues under an approved
Institutional Review Board protocol at the University of Pennsylvania. Human gingival and
skin tissues were treated aseptically and incubated overnight at 4°C with dispase (2 mg/ml)
to separate the epithelial and lower spinous layers. The tissues were minced into 1- to 3mm2 fragments and digested at 37°C for 2 hours in sterile PBS containing collagenase IV (4
mg/ml) (Worthington Biochemical). The dissociated cell suspension was filtered through a
70-µm cell strainer; plated in 100-mm culture dishes with !-MEM containing 10% FBS,
penicillin (100 U ml−1), streptomycin (100 µg ml−1), 2 mM l-glutamine, and 10 mM lascorbic acid phosphate; and cultured at 37°C in a humidified tissue culture incubator with
5% CO2. After 48 hours, the nonadherent cells were removed. The plastic-adherent
confluent cells were passaged with 0.05% trypsin containing 1 mM EDTA and continuously
subcultured and maintained in the complete growth medium.
Isolation and characterization of EVs
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Cells were cultured in exosome-depleted medium (complete medium depleted of FBSderived exosomes by overnight centrifugation at 100,000g) for 48 hours. EVs from culture
supernatants of 12 × 106 MSCs were isolated by differential centrifugation, as described in
the literature (35), at 300g for 10 min, 3000g for 10 min, 20,000g for 30 min, and 120,000g
for 70 min. After differential centrifugation, we used a sucrose cushion to purify sEVs as
described in previous literature (35, 36, 81, 82). Briefly, a crude sEV pellet from 12 × 106
cells was resuspended in PBS, underlain by a single cushion composed of 30% sucrose
prepared in tris/D2O, and centrifuged at 110,000g for 3 hours at 4°C. The ability of D2O to
readily diffuse with H2O across the discontinuous interphase allowed for the formation of a
continuous minigradient between 1.10 and 1.18 g/cm3 (82), which matched the ideal
gradients for MSC exosome isolation (37). The sEVs captured within the sucrose layer were
collected, washed with PBS twice, and centrifuged at 110,000g for 90 min at 4°C. The
purified sEVs were further verified by transmission electron microscopy and Western
blotting analysis. For analysis of exosome protein secretion, we used a Bradford protein
assay (Bio-Rad Laboratories) to measure the amount of total protein in purified exosomes
from 12 × 106 MSCs. Total exosome protein was normalized to 1 × 106 cells to show the
amount as micrograms per 1 × 106 cells. To further confirm exosomes containing IL-1RA,
sucrose gradient–purified exosomes were collected as previously described (37, 83). Briefly,
a crude exosome pellet from 24 × 106 cells was mixed with 2.5 M sucrose, loaded at the
bottom of an ultracentrifuge tube, and overlaid with a gradient of decreasing concentrations
of sucrose (2.0 to 0.4 M). Tubes were centrifuged for 16 hours at 4°C at 200,000g. After
centrifugation, 10 fractions were collected from the top of the tube. Total proteins from the
concentrated fractions were loaded for Western blotting analysis to detect IL-1RA.
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Full-thickness circular gingival wounds with a diameter of 1.5 mm were made in the palates
of the mice with a biopsy punch. Full-thickness square excision wounds (1 cm × 1 cm) were
created by marking the area of the wound on the mid-backs of the mice with a fine marker
and a ruler, lifting the skin with a pair of a forceps, and excising the full-thickness skin along
the lines with a pair of surgical scissors. To create circular cutaneous wounds, 4-mmdiameter full-thickness wounds were made in the mid-backs of the mice with a biopsy
punch. After the surgery on day 1, the wounds were topically submucosally injected with
placebo (0.9% saline), IL-1RA neutralizing antibody (10 µg per mouse), or IL-1RA drug
(anakinra, 100 µg per mouse for gingival wounds and 500 µg per mouse for cutaneous
wounds). For in vivo sEV treatments of gingival wounds, the wounds were submucosally
injected with either placebo or sEVs (40 µg) suspended in PBS (40 µl). For cutaneous
wounds, the wounds were subcutaneously injected with either placebo or sEVs (200 µg)
suspended in PBS (200 µl) on the basis of previous reports (25, 26). The gingival wound
images were taken via a stereoscope after sacrifice of the animal at the indicated time point.
A series of digital photographs of the cutaneous wounds was taken, including a ruler for
scale. At the indicated time points, the wound areas (for gingival wounds) or percentage of
wound closure (for cutaneous wounds) was quantified on photographs using Adobe
Photoshop 7.0.1 software (Adobe Systems). Changes in the area of the cutaneous wounds
were expressed as a percentage of the initial wound area.
Western blotting
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Cells and purified exosomes were lysed in M-PER mammalian protein extraction reagent
(Thermo Fisher Scientific) with protease and phosphatase inhibitors (Roche), and proteins
were quantified using a protein concentration assay (Bio-Rad Laboratories). For Western
blotting of cell lysis, 20 µg of proteins was separated by SDS–polyacrylamide gel
electrophoresis and transferred to 0.2-µm nitrocellulose membranes (Millipore). For Western
blotting analysis of exosome, exosome protein was isolated from the culture supernatant of 4
× 106 cells, and 10 µg of total exosome proteins was loaded. The membranes were blocked
with 5% nonfat dry milk and 0.1% Tween 20 for 1 hour, followed by incubation overnight
with the primary antibodies diluted in blocking solution according to the manufacturer’s
instructions. Antibodies to mouse Fas (05–351) were purchased from Millipore. Antibodies
to mouse Fap-1 (sc-15356), Cav-1 (sc-894), and SNAP25 (sc-7538) were purchased from
Santa Cruz Biotechnology. Antibodies to mouse IL-1RA (ab124962) and VAMP5 (ab85581)
were purchased from Abcam. Antibody to mouse #-actin (A5441) was purchased from
Sigma-Aldrich. The membranes were then incubated under room temperature for 1 hour in
species-related horseradish peroxidase–conjugated secondary antibody (Santa Cruz
Biotechnology) diluted at 1:10,000 in blocking solution. Immunoreactive proteins were
detected using SuperSignal West Pico Chemiluminescent Substrate (Thermo Fisher
Scientific) and Biomax film (Kodak); the sensitivity of this substrate can be used to detect
low-picogram amounts of protein in polyvinylidene difluoride membrane. The relative
density was measured using ImageJ 1.49v software (Wayne Rasband). The quantification of
Western blotting for total EV protein was normalized against the control group or GMSC
group, and the quantification of the other Western blotting experiments was normalized
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against loading control #-actin. Western blotting films corresponding to Figs. 1 to 4 are
shown in database S1.
Immunoprecipitation
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Cells were lysed in M-PER mammalian protein extraction reagent (Thermo Fisher
Scientific) with protease and phosphatase inhibitors (Roche), and proteins were quantified
using a protein concentration assay (Bio-Rad Laboratories). One microgram of the
appropriate control immunoglobulin G, together with 20 µl of resuspended protein A/G
PLUS-Agarose, was added to precleared lysate and incubated at 4°C for 30 min. Pellet
beads were centrifuged at 2500 rpm for 5 min at 4°C, and the supernatant with total cellular
protein (300 µg) was transferred to a fresh centrifuge tube on ice. Primary antibody was
added and incubated overnight at 4°C. Twenty microliters of resuspended protein A/G
PLUS-Agarose was added at 4°C. After 2 hours, the tubes were centrifuged at 2500 rpm for
5 min at 4°C and the immunoprecipitates were collected. The beads were pelleted and
washed with radioimmunoprecipitation assay buffer. Beads were then pelleted, washed, and
resuspended in 40 µl of electrophoresis sample buffer. The samples were boiled at 90°C for
5 min, and 20-µl aliquots were subjected to Western blotting analysis.
siRNA knockdown, CRISPR/Cas9 knockout, and cytokine treatments
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For siRNA knockdown, GMSCs (0.2 × 106) were seeded on a six-well culture plate. Fas,
FAP-1, Cav-1, SNAP25, and VAMP5 siRNAs (Santa Cruz Biotechnology) were used to treat
the GMSCs according to the manufacturer’s instructions. Nontargeting control siRNAs
(Santa Cruz Biotechnology) were used as negative controls. Fap-1 CRISPR (clustered
regularly interspaced short palindromic repeats)/Cas9 (CRISPR-associated protein 9)
knockout plasmid (sc-422505, Santa Cruz Biotechnology) was used to knock out Fap-1
expression in GMSCs according to the manufacturer’s instructions. Briefly, GMSCs (0.2 ×
106) were seeded on a six-well culture plate. The cells were allowed to grow to 40 to 80%
confluence and then transfected with Fap-1 CRISPR/Cas9 knockout plasmids using
Lipofectamine LTX with Plus reagent (Life Technologies) according to the manufacturer’s
instructions. Scrambled guide RNA CRISPR/Cas9 plasmids were used as a negative control.
The efficiency of siRNA knockdown and CRISPR/Cas9 knockout was confirmed by
Western blot analysis. For cytokine treatments, GMSCs were treated with different
concentrations of IFN-$ and TNF-! (Peprotech; 0, 20, 50, 100, and 200 ng/ml) or TNF-!
(20 ng/ml) for 24 hours. After transfection or cytokine treatment, cells were used for protein
extraction for Western immunoblotting, and the culture supernatants were used for ELISA.
Plasmid transfection, TIRF, and STED microscopy
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For protein tracing, IL-1RA–EGFP fusion protein expression plasmids (System Biosciences)
and CD63-mCherry fusion protein expression plasmids (a gift from C.G., University of
Pennsylvania) were used. Empty plasmids with the same backbone were used as a control.
The cells were transfected with plasmids using Lipofectamine LTX with Plus reagent (Life
Technologies) according to the manufacturer’s instructions. For IL-1RA–positive vesicle
colocalization studies, WT GMSCs were transfected with plasmids expressing IL-1RA–
EGFP fusion protein and fixed with 4% paraformaldehyde. Next, the cells were incubated
with anti-CD63 or anti-CD81 antibodies and imaged using a super-resolution STED
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microscope (Leica Microsystems). To visualize IL-1RA–positive vesicle dynamics, WT
GMSCs were transfected with plasmids expressing IL-1RA–EGFP fusion protein, and the
vesicular organelles were stained with LysoTracker. To visualize IL-1RA–positive exosome
dynamics, WT GMSCs were cotransfected with plasmids expressing IL-1RA–EGFP fusion
protein and CD63-mCherry fluorescent protein. Forty-eight hours after transfection, the
GMSCs were treated with TNF-! (20 ng/ml), and the dynamics of IL-1RA–positive
microvesicle exocytosis were monitored in living GMSCs using TIRF microscopy. Briefly,
about 3.0 × 104 transfected cells were plated on an eight-well chambered cover glass (LabTek II, Nunc) in the imaging medium Dulbecco’s modified Eagle’s medium–Hepes without
phenol red (Thermo Fisher Scientific). Cells were imaged at a rate of 1 frame/s using a Leica
TIRF microscope equipped with adaptive focus control and an environmental control system
set to 5% CO2 and 37°C. Fluorophores were excited with solid-state 488- and 561-nm
lasers, TIRF angle was set to 90 nm depth, and images were acquired using a Photometrics
Evolve EMCCD camera. Images were analyzed and processed using FIJI software.
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Statistics
Comparisons between two groups were analyzed using independent unpaired two-tailed
Student’s t tests, and comparisons between more than two groups were analyzed using oneway analysis of variance (ANOVA) with Bonferroni correction. P values less than 0.05 were
considered statistically significant.
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Fig. 1. Murine gingival MSCs and skin MSCs produce and secrete IL-1RA–EV.
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(A) Total protein contained within small extracellular vesicles (sEVs) isolated from the
culture supernatant of 1 × 106 murine human bone marrow mesenchymal stem cells
(BMMSCs), gingiva-derived MSCs (GMSCs), and skin MSCs (SMSCs) (n = 3). (B)
Western blotting and semi-quantification analysis of CD63, CD9, and CD81 expression from
sEVs isolated from GMSCs and SMSCs. (C) Differential centrifugation and sucrose cushion
procedure for the isolation of EVs from MSC culture supernatants (SN). (D) Interleukin-1
receptor antagonist (IL-1RA), CD63, CD9, and CD81 expression in lysates from fractions
corresponding to (C). (E) Super-resolution stimulated emission depletion staining and
quantification for IL-1RA–enhanced green fluorescent protein (EGFP) (green), CD63 (red),
and CD81 (red) in GMSCs transfected with plasmids containing IL-1RA–EGFP fusion
protein. The lower right box is a higher magnification of the boxed region in the merged
image; colocalization of IL-1RA with CD63 or CD81 is shown in yellow (n = 5). Scale bar,
10 µm. (F) Total internal reflection fluorescence (TIRF) microscopy images from GMSCs
cotransfected with plasmids expressing IL-1RA–EGFP (green) and CD63-mCherry (red).
The top right panel is a higher magnification of the boxed region in the left image;
colocalization of IL-1RA–EGFP and CD63-mCherry is shown in yellow. The bottom panels
(1 to 4) show sequential images from live-cell imaging. Arrows indicate two individual
IL-1RA–positive vesicle fusion events. Scale bar, 10 µm. (G) Enzyme-linked
immunosorbent assay (ELISA) of IL-1RA from the culture supernatant of GMSCs and
SMSCs (n = 3). (H) Western blotting and semi-quantification analysis of IL-1RA expressed
by GMSCs and SMSCs. (I) Immunocytofluorescence staining of IL-1RA (green) and the
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MSC marker CD105 (red) in GMSCs and SMSCs. Scale bar, 20 µm. (J and K) Real-time
polymerase chain reaction analysis of soluble IL-1RA (sIL-1RA) mRNA (J) and
intracellular IL-1RA (icIL-1RA) mRNA (K) in GMSCs and SMSCs. All results are
representative of data generated in at least three independent experiments (J and K) (n = 6).
**P < 0.01, ***P < 0.001. Error bars are means ± SD. Data were analyzed using one-way
analysis of variance (ANOVA) with Bonferroni correction (A), or independent un-paired
two-tailed Student’s t tests (B, G, H, J, and K).
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Fig. 2. Fas controls IL-1RA–sEV secretion in murine MSCs.
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(A) Western blotting and semi-quantification of Fas expression in GMSCs and SMSCs (n =
3). (B) Secreted sEV-associated protein quantification from Fas-deficient MRL/lpr and wildtype (WT) control GMSCs (n = 5). (C) Western blotting and semi-quantification analysis of
CD63, CD9, CD81, and IL-1RA from sEV from Fas-deficient MRL/lpr and WT control
GMSCs. sEV-associated proteins from culture supernatants of equal numbers of cells in
control and MRL/lpr GMSC groups were loaded (n = 3). (D) ELISA analysis of secreted
IL-1RA from the culture supernatant from WT control and Fas-deficient MRL/lpr GMSCs
(n = 3). (E) Western blotting and semi-quantification analysis of cytoplasmic IL-1RA from
WT control and Fas-deficient MRL/lpr GMSCs (n = 3). (F) Immunocytofluorescent double
staining of IL-1RA (green) and Fas (red) in WT control and Fas-deficient MRL/lpr GMSCs.
Dashed lines indicate the cell edge. Scale bar, 20 µm. (G) ELISA analysis of IL-1RA
secretion in the culture supernatant of MRL/lpr and Fas-overexpressing MRL/lpr GMSCs (n
= 5). (H) Western blotting and semi-quantification analysis of cytoplasmic IL-1RA from
MRL/lpr and Fas-overexpressing MRL/lpr GMSCs (n = 3). (I) ELISA analysis of IL-1RA
secretion in the culture supernatant from WT control GMSCs treated with and without Fas
small interfering (siRNA) (n = 5). (J) Western blotting and semi-quantification of
cytoplasmic IL-1RA and Fas from WT control GMSCs treated with or without Fas siRNA (n
= 3). All results are representative of data generated from at least three independent
experiments. **P < 0.01, ***P < 0.001. Error bars are means ± SD. All data were analyzed
using independent unpaired two-tailed Student’s t tests.
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Fig. 3. Fas binds with Fap-1 and Cav-1 to regulate IL-1RA–sEV release in murine GMSCs.

Author Manuscript
Author Manuscript

(A) Fas co-IP of WT control and MRL/lpr GMSC lysate. (B) Immunocytofluorescence
double staining for Fas, Fap-1, and Cav-1 in WT GMSCs. (C) Secreted sEV-associated
protein quantification from WT control, Fap-1, and Cav-1 knockout GMSCs (n = 3). (D)
Western blotting and semi-quantification of CD63, CD9, CD81, and IL-1RA in sEVs from
WT control, Fap-1, and Cav-1 knockout GMSCs. Culture supernatants from equal numbers
of cells from control and knockout GMSCs were loaded for Western blotting analysis (n =
3). (E) Western blotting and semi-quantification of Fas, Fap-1, Cav-1, and IL-1RA
expression in WT control, MRL/lpr, Fas-deficient, Fap-1 knockout, and Cav-1 knockout
GMSCs (n = 3). (F) ELISA analysis of secretion of IL-1RA in the culture supernatant from
WT control, Fap-1–deficient, and Cav-1–deficient GMSCs (n = 5). (G) Immunoprecipitation
(IP) and semi-quantification analysis of Fas from WT control, Fap-1–deficient, and Cav-1
knockout GMSC lysates (n = 3). (H) IP and semi-quantification analysis of Fap-1 from WT
control, MRL/lpr, Cav-1 knockout, and Fap-1 knockout GMSC lysates (n = 3). (I) IP and
semi-quantification analysis of Cav-1 from WT control, MRL/lpr, Fap-1 knockout, and
Cav-1 knockout GMSCs (n = 3). (J) Immunocytofluorescence staining of Cav-1 in WT, Fasdeficient MRL/lpr, and Fap-1 knockout GMSCs, and double-staining of Fap-1 and Fas in
WT and Cav-1 knockout GMSCs. For A-P, Fas-deficient GMSCs from MRL/lpr mice,
GMSCs with Fap-1 knocked out using a CRISPR (clustered regularly interspaced short
palindromic repeats)/Cas9 (CRISPR-associated protein 9) plasmid, and Cav-1 knockout
GMSCs from Cav-1−/− mice were used, and WT GMSCs served as a control. For IP, wholeSci Transl Med. Author manuscript; available in PMC 2018 December 28.
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cell lysates from indicated GMSCs were immunoprecipitated with corresponding antibodies,
and the immunocomplexes were subjected to Western blotting with antibodies against Fas,
Fap-1, and Cav-1. All results are representative of data generated from three independent
experiments. *P < 0.05, **P < 0.01, ***P < 0.001. Error bars are means ± SD. Scale bars,
20 µm. All data were analyzed using independent unpaired two-tailed Student’s t tests.
DAPI, 4%,6-diamidino-2-phenylindole; IgG, immunoglobulin G.
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Fig. 4. TNF-! up-regulates Fas/Fap-1 expression to promote IL-1RA–sEV release in murine
MSCs.
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(A) ELISA analysis of IL-1RA secretion into the culture supernatant from GMSCs treated
with tumor necrosis factor–! (TNF-!) or interferon-$ (IFN-$) (n = 3). (B) Secreted sEVassociated proteins from control or TNF-! (20 ng/ml)–treated GMSCs (n = 6). (C) Western
blotting and semi-quantification of CD63, CD9, CD81, and IL-1RA expression in WT
control GMSCs with or without TNF-! (20 ng/ml) treatment. sEV-associated proteins from
culture supernatants of equal numbers of cells were loaded for Western blotting analysis (n =
3). (D) Western blotting and semi-quantification analysis of Fas, Fap-1, Cav-1, and IL-1RA
expression in WT GMSCs (left) and MRL/lpr GMSCs (right) treated with or without TNF-!
(n = 3). (E) ELISA analysis of secretion of IL-1RA in the culture supernatant in control or
MRL/lpr GMSCs treated with and without TNF-! (20 ng/ml) (n = 3). (F) Western blotting
and semi-quantification of Fas, Cav-1, and IL-1RA in Fap-1 knockout GMSCs with and
without TNF-! (20 ng/ml) treatment (n = 3). (G) Western blotting and semi-quantification
of Fas, Fap-1, and IL-1RA in Cav-1 knockout GMSCs with and without TNF-! (20 ng/ml)
treatment (n = 3). (H) ELISA analysis of IL-1RA in the culture supernatant of WT control,
Fap-1, and Cav-1 knockout GMSCs treated with and without TNF-! (20 ng/ml) (n = 3). (I)
Immunocytofluorescence staining of GMSCs at various time points after TNF-! (20 ng/ml)
treatment. Scale bar, 20 µm. (J) Western blotting and semi-quantification analysis of Fas,
Fap-1, and Cav-1 in membrane and cytoplasmic fractions of GMSCs treated with and
without TNF-! (20 ng/ml) (n = 3). (K) TIRF microscopy images of IL-1RA–EGFP (green)

Sci Transl Med. Author manuscript; available in PMC 2018 December 28.

Kou et al.

Page 28

Author Manuscript

and CD63-mCherry (red) cotransfected into WT GMSCs treated with TNF-! (20 ng/ml) for
0.5 hours. The top left panel is a higher magnification of the boxed region in the left image
to show colocalization (yellow); the bottom panels show sequential images (1 to 4). Arrows
indicate two individual IL-1RA–positive vesicle fusion events. Scale bar, 10 µm. *P < 0.05,
**P < 0.01, ***P < 0.001. Error bars are means ± SD. Data were analyzed using
independent unpaired two-tailed Student’s t tests (A to D, F, G, and J), or one-way ANOVA
with Bonferroni correction (E and H).
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Fig. 5. GMSCs produce IL-1RA, which contributes to gingival wound healing in mice.
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(A) Scheme illustrating the gingival wound procedure and treatment with IL-1RA
neutralizing antibody. Full-thickness circular wounds were made in the palates of WT
control mice and IL-1RA−/− mice and submucosally injected one time with placebo (0.9%
saline) or IL-1RA neutralizing antibody (IL-1RA Ab, 10 µg per mouse) 1 day after wound
creation. (B) Representative macroscopic images and quantification of gingival wound area
in WT control and IL-1RA−/− mice. All the gingival wound is outlined in a dashed line (n =
5). (C) Representative macroscopic images and quantification of gingival wound area in WT
mice after treatment with or without IL-1RA Ab (n = 5). (D) Representative macroscopic
images and quantification of gingival wound area in WT mice after treatment with or
without IL-1RA drug (n = 5). (E) Scheme illustrating cutaneous wound procedure and
treatment with IL-1RA drug anakinra. Full-thickness excision cutaneous wounds (1 cm × 1
cm) were created in the mid-backs of WT mice. One day after wound creation, the mice
were subcutaneously injected with either placebo (0.9% saline) or the IL-1RA drug anakinra
(500 µg per mouse). (F) Representative macroscopic images and quantification of closure of
full-thickness cutaneous wounds in WT mice after treatment with or without anakinra (n =
5). (G) Scheme illustrating the gingival wound procedure and administration of sEVs.
IL-1RA knockout mice were submucosally injected with placebo (0.9% saline) or WT
GMSC–derived, IL-1RA knockout GMSC–derived, or TNF-!–activated GMSC-derived
sEVs 1 day after wound creation. (H) Representative macroscopic images and quantification
of gingival wound area in IL-1RA knockout mice after treatment with or without sEVs (n =
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3 for day 7; n = 5 for day 5). *P < 0.05, **P < 0.01, ***P < 0.001. Error bars are means ±
SD. Data were analyzed using independent unpaired two-tailed Student’s t tests (B to F) or
one-way ANOVA with Bonferroni correction (H).
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Fig. 6. Fas-controlled IL-1RA secretion regulates wound healing in mice.
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(A) Scheme illustrating the gingival wound procedure in MRL/lpr mice and treatment with
the IL-1RA drug anakinra. Full-thickness circular wounds were made in the palates of WT
and MRL/lpr mice with a biopsy punch, and MRL/lpr mice were submucosally injected with
either placebo (0.9% saline) or the IL-1RA drug anakinra (100 µg per mouse) 1 day after
wound creation. (B) Representative macroscopic images and quantification of gingival
wound area in WT and MRL/lpr mice after treatment with and without anakinra (n = 5). (C)
Representative macroscopic images and quantification of dermal wound area in WT and
MRL/lpr mice over time (n = 3). (D) Representative macroscopic images and quantification
of dermal wound area in MRL/lpr mice treated with placebo (0.9% saline) or anakinra (500
µg per mice) injected 1 day after wound creation as in (A) (n = 3). **P < 0.01, ***P < 0.001.
Error bars are means ± SD. Data were analyzed using one-way ANOVA with Bonferroni
correction (B) or independent unpaired two-tailed Student’s t tests (C and D).
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